Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β₂-agonist) in asthma patients: a narrative review

References

• Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1. doi:10.1186/s40733-016-0029-3.
   PubMedGoogle Scholar
• Yaghoubi M, Adibi A, Safari A, FitzGerald JM, Sadatsafavi M. The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med. 2019;200(9):1102–1112. doi:10.1164/rccm.201901-0016OC.
   PubMed Web of Science ®Google Scholar
• Buhl R, Heaney LG, Loefroth E, Larbig M, Kostikas K, Conti V, Cao H. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respir Med. 2020;162:105859. doi:10.1016/j.rmed.2019.105859.
   PubMed Web of Science ®Google Scholar
• GINA. Global Strategy for Asthma Management and Prevention. 2022. update. Available from: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf [last accessed 10 June 2022].
   Google Scholar
• Oppenheimer J, Slade DJ, Hahn BA, Zografos L, Gilsenan A, Richardson D, McSorley D, Lima R, Molfino NA, Averell CM. Real-world evidence: patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021;126(4):385–393.e2. doi:10.1016/j.anai.2020.12.015.
   PubMed Web of Science ®Google Scholar
• Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100(7):1139–1151. doi:10.1016/j.rmed.2006.03.031.
   PubMed Web of Science ®Google Scholar
• Cloutier MM, Baptist AP, Blake KV, Brooks EG, Bryant-Stephens T, DiMango E, Dixon AE, Elward KS, Hartert T, Krishnan JA, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146(6):1217–1270. doi:10.1016/j.jaci.2020.10.003.
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. doi:10.1016/S2213-2600(20)30389-1.
   PubMed Web of Science ®Google Scholar
• Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma – a narrative review. Eur J Intern Med. 2021;85:14–22. doi:10.1016/j.ejim.2021.01.027.
   PubMed Web of Science ®Google Scholar
• Virchow JC. Assessing the benefits of triple versus dual fixed-dose combinations for the treatment of severe asthma. Lancet Respir Med. 2020;8(10):937–939. doi:10.1016/S2213-2600(20)30303-9.
   PubMed Web of Science ®Google Scholar
• Luz MI, Aguiar R, Morais-Almeida M. The reality of LAMAs for adult asthmatic patients. Expert Rev Respir Med. 2020;14(11):1087–1094. doi:10.1080/17476348.2020.1794828.
   PubMed Web of Science ®Google Scholar
• Seymour CW, Gomez H, Chang CH, Clermont G, Kellum JA, Kennedy J, Yende S, Angus DC. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017;21(1):257. doi:10.1186/s13054-017-1836-5.
   PubMedGoogle Scholar
• Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, et al. Mometasone or tiotropium in mild asthma with a low sputum eosinophil level. N Engl J Med. 2019;380(21):2009–2019. doi:10.1056/NEJMoa1814917.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Puxeddu E, Matera MG, Rogliani P. A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019;13(11):1079–1085. doi:10.1080/17476348.2019.1657408.
   PubMed Web of Science ®Google Scholar
• Casale TB, Bateman ED, Vandewalker M, Virchow JC, Schmidt H, Engel M, Moroni-Zentgraf P, Kerstjens HAM. Tiotropium Respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract. 2018;6(3):923–935.e9. doi:10.1016/j.jaip.2017.08.037.
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri L, Lahousse L, Singh D, Papi A. Single inhaler triple therapy (SITT) in asthma: systematic review and practice implications. Allergy. 2022;77(4):1105–1113. doi:10.1111/all.15076.
   PubMed Web of Science ®Google Scholar
• NHLBI, NIH. 2020. Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Available from: https://nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates [last accessed 10 October 2021].
   Google Scholar
• Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, Schmidt H, Engel M, Bateman ED. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206. doi:10.1016/j.rmed.2016.06.013.
   PubMed Web of Science ®Google Scholar
• Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: a narrative review. Respirology. 2020;25(2):161–172. doi:10.1111/resp.13730.
   PubMed Web of Science ®Google Scholar
• Aalbers R, Park HS. Positioning of long-acting muscarinic antagonists in the management of asthma. Allergy Asthma Immunol Res. 2017;9(5):386–393. doi:10.4168/aair.2017.9.5.386.
   PubMed Web of Science ®Google Scholar
• Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006;533(1-3):36–39. doi:10.1016/j.ejphar.2005.12.072.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, Sigmund R, Seibold W, Moroni-Zentgraf P, Bateman ED. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207. doi:10.1056/NEJMoa1208606.
   PubMed Web of Science ®Google Scholar
• Wang K, Tian P, Fan Y, Wang Y, Liu C. Assessment of second-line treatments for patients with uncontrolled moderate asthma. Int J Clin Exp Med. 2015;8:19476–19480.
   PubMed Web of Science ®Google Scholar
• Ohta K, Ichinose M, Tohda Y, Engel M, Moroni-Zentgraf P, Kunimitsu S, Sakamoto W, Adachi M. Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study. PLoS ONE. 2015;10(4):e0124109. doi:10.1371/journal.pone.0124109.
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Bernstein JA, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A, Engel M, Boner AL. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49(1):1601100. doi:10.1183/13993003.01100-2016.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. SPIRIVA® RESPIMAT® (Tiotropium bromide). Inhalation spray. 2004. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Spiriva%20Respimat/spirivarespimat.pdf [last accessed 22 August 2022].
   Google Scholar
• Kaplan A, Chang K-L. Tiotropium in asthma – perspectives for the primary care physician. Postgrad Med. 2021;133(5):552–564. doi:10.1080/00325481.2020.1816329.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, Engel M, Bour L, Verkleij CB, Moroni-Zentgraf P, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–376. doi:10.1016/S2213-2600(15)00031-4.
   PubMed Web of Science ®Google Scholar
• George M, Bender B. New insights to improve treatment adherence in asthma and COPD. Patient Prefer Adherence. 2019;13:1325–1334. doi:10.2147/PPA.S209532.
   PubMed Web of Science ®Google Scholar
• Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:417–438. doi:10.2147/COPD.S234823.
   PubMed Web of Science ®Google Scholar
• Stanford RH, Averell C, Parker ED, Blauer-Peterson C, Reinsch TK, Buikema AR. Assessment of adherence and asthma medication ratio for a once-daily and twice-daily inhaled corticosteroid/long-acting β2-agonist for asthma. J Allergy Clin Immunol Pract. 2019;7(5):1488–1496.e7. doi:10.1016/j.jaip.2018.12.021.
   PubMed Web of Science ®Google Scholar
• Rajesh V, Augustine J, Divya R, Cleetus M. Inhaled formoterol-fluticasone single inhaler therapy in asthma: real-world efficacy, budget impact, and potential to improve adherence. Can Respir J. 2020;2020:1–8. doi:10.1155/2020/8631316.
   Web of Science ®Google Scholar
• Singh D, Virchow JC, Canonica GW, Vele A, Kots M, Georges G, Papi A. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur Respir J. 2020;56(3):2000476. doi:10.1183/13993003.00476-2020.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. doi:10.1016/S0140-6736(19)32215-9.
   PubMed Web of Science ®Google Scholar
• Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170:106021. doi:10.1016/j.rmed.2020.106021.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D’Andrea P. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi:10.1016/S2213-2600(20)30190-9.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Calzetta L. Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. Eur Respir J. 2021;58(3):2004233. doi:10.1183/13993003.04233-2020.
   PubMed Web of Science ®Google Scholar
• Gosens R, Gross N. The mode of action of anticholinergics in asthma. Eur Respir J. 2018;52(4):1701247. doi:10.1183/13993003.01247-2017.
   PubMed Web of Science ®Google Scholar
• Gosens R, Nelemans SA, Grootte Bromhaar MM, McKay S, Zaagsma J, Meurs H. Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003;28(2):257–262. doi:10.1165/rcmb.2002-0128OC.
   PubMed Web of Science ®Google Scholar
• Gosens R, Dueck G, Rector E, Nunes RO, Gerthoffer WT, Unruh H, Zaagsma J, Meurs H, Halayko AJ. Cooperative regulation of GSK-3 by muscarinic and PDGF receptors is associated with airway myocyte proliferation. Am J Physiol Lung Cell Mol Physiol. 2007;293(5):L1348–L1358. doi:10.1152/ajplung.00346.2007.
   PubMed Web of Science ®Google Scholar
• Bos IS, Gosens R, Zuidhof AB, Schaafsma D, Halayko AJ, Meurs H, Zaagsma J. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J. 2007;30(4):653–661. doi:10.1183/09031936.00004907.
   PubMed Web of Science ®Google Scholar
• Matera MG, Belardo C, Rinaldi M, Rinaldi B, Cazzola M. New perspectives on the role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2020;14(8):817–824. doi:10.1080/17476348.2020.1758069.
   PubMed Web of Science ®Google Scholar
• Baan EJ, Hoeve CE, De Ridder M, Demoen L, Lahousse L, Brusselle GG, Verhamme KMC. The ALPACA study: (In)Appropriate LAMA prescribing in asthma: a cohort analysis. Pulm Pharmacol Ther. 2021;71:102074. doi:10.1016/j.pupt.2021.102074.
   PubMed Web of Science ®Google Scholar
• Casale TB, Foggs MB, Balkissoon RC. Optimizing asthma management: role of long-acting muscarinic antagonists. J Allergy Clin Immunol. 2022;150(3):557–568. doi:10.1016/j.jaci.2022.06.015.
   PubMed Web of Science ®Google Scholar
• Kaplan A, FitzGerald JM, Buhl R, Vogelberg C, Hamelmann E. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management. NPJ Prim Care Respir Med. 2020;30(1):50. doi:10.1038/s41533-020-00205-9.
   PubMed Web of Science ®Google Scholar
• Pulmonology Advisor. Treating Severe Uncontrolled Asthma: Can Single-Inhaler, Fixed Triple-Dose Therapy Improve Outcomes? Available from: https://www.pulmonologyadvisor.com/howtotreat/treating-severe-uncontrolled-asthma-can-single-inhaler-fixed-triple-dose-therapy-improve-outcomes/ [last accessed 22 October 2021].
   Google Scholar